Accelerating Progress in the Development of Vaccines

Over 1500 people registered for the 2nd Vaccine Global Congress and 1st Vaccine Virtual Congress

Amsterdam, December 10, 2008 – This week the Elsevier Journal Vaccine, the most comprehensive and pre-eminent journal for those interested in vaccines and vaccination, organized the 2nd Vaccine Global Congress in Boston MA, USA. For those people who could not attend the congress in Boston, the 1st Vaccine Virtual Congress was offered. This innovative alternative was very well received and enabled access to relevant research and the opportunity to connect with other vaccinologists.

The 2nd Vaccine Global Congress, organized in collaboration with the International Society for Vaccines, attracted a mix of scientists, governmental authorities and healthcare workers and provided a broad state-of-the-art report. The scene was set by presentations on vaccines for the main infectious diseases HIV/AIDS, Malaria and Tuberculosis which kill 5 million people each year. Next to these major disease targets, sessions addressed topics such as cancer vaccines, adjuvants, delivery systems, vaccine policy and public health issues. “I was delighted to see so many people from different areas, all with the common objective of accelerating progress in the research, development and delivery of vaccines”, said Professor Shan Lu from the University of Massachusetts Medical School in Worchester MA, USA and co-chairman of the congress; “The science presented was excellent and will form the basis for an increasingly needed prophylactic approach to healthcare”.

With over 1100 pre-registrants, the 1st Vaccine Virtual Congress was also considered a huge success. Academics in research and development, regulatory and governmental agencies, charities, and health and industry professionals attended the congress from their desk at home or in the office. They were able to join live keynote presentations and submit questions in real time, review and download posters, network and chat with their online peers, and navigate the show via a virtual fully interactive platform.

“Together with ON24, the global leader in webcasting and virtual events solutions, we were able to create an interactive environment where delegates could access educational information and collaborate with peers regardless of physical boundaries, said Nigel Clair, Commercial Director of Elsevier, “in addition, people who registered can still access the content for another 3 months”. Registration for the Vaccine Virtual Congress is still possible and free.

“As a professional congress organizer Elsevier is always aiming to provide delegates an excellent environment to hear presentations, network with peers and access rich information”, said Nigel, “specifically, we will continue to strengthen our relationship with the important vaccine community and I already look forward to the 3rd Vaccine Global Congress that will be held early October 2009 in Bangkok, Thailand”.

###

About Vaccine
Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It serves as an interface between academics, those in research and development, and workers in the field. Relevant topics range from basic research through to applications, safety and legislation. About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Floris de Hon
Elsevier
+31 (0) 20 485 2498
f.hon@elsevier.com